Scalp Application of Red and Near-Infrared Light, From Light-Emitting Diodes (LED) to Improve Thinking and Memory in Veterans With Gulf War Illnesses (LED Treat GWVI)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to learn if an experimental treatment can help thinking ability, and memory in Veterans with Gulf War Veterans Illnesses (GWVI). The experimental treatment is called transcranial, light-emitting diodes (LEDs), that are applied outside the skull, to the head. The LEDs are applied to three sets of placements on the head. Each placement set is treated for 6 and a half minutes. The participants receive a series of LED treatments which take place as outpatient visits at the VA Boston Healthcare System, Jamaica Plain Campus. The LEDs contain red and near-infrared diodes. The FDA considers the LED device used here, to be a non-significant risk device. The LEDs do not produce heat.
| Condition | Intervention | Phase |
|---|---|---|
|
Persian Gulf Syndrome Neurobehavioral Manifestations Memory Disorders |
Device: Photomedex Helmet, with Red/Near-Infrared Light-Emitting Diodes (LEDs) |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Transcranial, Light-Emitting Diode (LED) Therapy to Improve Cognition in GWVI |
- Attention/Executive Function [ Time Frame: 1 Week after the last LED treatment in each treatment series ] [ Designated as safety issue: No ]Stroop Test ("Color-Word" test) (Delis, Kaplan & Kramer, 2001)
- Additional Attention/Executive Function [ Time Frame: 1 Week after the last LED treatment in each treatment series ] [ Designated as safety issue: No ]Digit Span Subtests (WAIS-IV; Wechsler, 2008) D-KEF Trails (Delis, Kaplan & Kramer, 2001)
- Learning and Memory [ Time Frame: 1 Week after the last LED treatment in each treatment series ] [ Designated as safety issue: No ]California Verbal Learning Test-II (CVLT-II; Delis, Kramer, Kaplan, & Ober, 2000)
- Mood [ Time Frame: 2 Months after the last LED treatment ] [ Designated as safety issue: No ]Beck Depression inventory (BDI; Beck, 2006)
- Data for General Physical Health [ Time Frame: 2 Months after the last LED treatment ] [ Designated as safety issue: No ]Short Form-36V Plus (Ware et al., 2000) Health Symptom Checklist (HSC). The HSC is a comprehensive list of 34 frequently reported health and mental health symptoms originally adapted from Bartone et al., (1989). It asks how often in the past 30 days each of the health symptoms was experienced. Symptoms from nine body systems are assessed (cardiac, pulmonary, dermatological, gastrointestinal, genitourinary, musculoskeletal, neurological, and psychological).
- Blood Tests [ Time Frame: Within 1 Week of the last LED treatment ] [ Designated as safety issue: No ]Tests for Mitochondrial Function Tests for Inflammation Tests for Coagulation Tests for General Health
| Estimated Enrollment: | 160 |
| Study Start Date: | March 2013 |
| Estimated Study Completion Date: | February 2017 |
| Estimated Primary Completion Date: | August 2016 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Real LED Treatment Series First
Participants in this group first receive a series of 15 real LED treatments with the helmet containing the real LEDs. At 1 week following the last real LED treatment, these participants then receive a series of 15 sham LED treatments with the helmet containing the sham LEDs.
|
Device: Photomedex Helmet, with Red/Near-Infrared Light-Emitting Diodes (LEDs)
The LED helmet from Photomedex, Montgomeryville, PA will be used. 18 LED pods are in the helmet. Each LED pod: Pod size: 19 cm2 Power output: 692.5 mW Power density: 36.5 mW/cm2 20 NIR diodes, 830 nm and 4 red diodes, 633 nm. 1 J/cm2 = 30.4 sec |
|
Sham Comparator: Sham LED Treatment Series First
Participants in this group first receive a series of 15 sham LED treatments with the helmet containing the sham LEDs. At 1 week following the last sham LED treatment, these participants then receive a series of 15 real LED treatments with the helmet containing the real LEDs.
|
Device: Photomedex Helmet, with Red/Near-Infrared Light-Emitting Diodes (LEDs)
The LED helmet from Photomedex, Montgomeryville, PA will be used. 18 LED pods are in the helmet. Each LED pod: Pod size: 19 cm2 Power output: 692.5 mW Power density: 36.5 mW/cm2 20 NIR diodes, 830 nm and 4 red diodes, 633 nm. 1 J/cm2 = 30.4 sec |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 38 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
The participants for this study will be recruited from the participants in a Department of Defense (DoD) study of a longitudinal cohort of Gulf War Veterans who returned from their deployment in 1991 through Ft. Devens, MA. This cohort has been followed at multiple time points since the end of war.
Participants will have answered 'Yes' to the following questions completed on the cohort survey: 1) Difficulty concentrating; and/or 2) Difficulty remembering recent information.
- Must be a veteran deployed in 1990-1991 Gulf War
- Meets criteria for GWVI as defined by "Symptom Questions used to identify Gulf War Illness by Kansas Case Definition, and Chronic Multisymptom Illness by Fukuda Case Definition" (Steele, 2000; Fukuda et al., 1998). Participants must have the presence of 1 or more chronic symptoms (lasting >6 months) from at least 2 of 3 symptom categories from Fukuda et al., (1998): 1) musculoskeletal (muscle pain, or joint pain, stiffness); 2) mood-cognition 3) fatigue.
- Ages 38 - 65 years
- Must be physically able to travel to the VA Boston Healthcare System, Jamaica Plain, for Neuropsychological testing and transcranial LED treatments
- Must meet screening criteria from the Neuropsychological Screening Tests
Exclusion Criteria:
- Not meeting criteria for GWVI as defined by Symptom Questions used to identify Gulf War Illness by Kansas Case Definition, and Chronic Multisymptom Illness by Fukuda Case Definition" (Steele, 2000; Fukuda et al., 1998).
- Had GWVI, but did not answer 'Yes' to the following questions: 1) Difficulty concentrating and/or 2) Difficulty remembering recent information, on the Symptom Questionnaire
- Less than age 38, or greater than age 65
- Presence of a neurodegenerative disease such as ALS, Parkinson's, Dementia
- Presence of a life-threatening disease such as cancer
- Presence of a severe mental disorder such as schizophrenia, or severe depression
- Physical limitations that would prevent traveling to the VA Boston Healthcare System, Jamaica Plain, for Neuropsychological testing and transcranial LED treatments
- Current substance abuse or active treatment
- Did not meet screening criteria from the Neuropsychological Screening Tests
Contacts and Locations| Contact: Ethan Treglia, MS | (857) 364-2631 | etreglia@bu.edu |
| United States, Massachusetts | |
| VA Medical Center, Jamaica Plain Campus | Not yet recruiting |
| Boston, Massachusetts, United States, 02130 | |
| Contact: Ethan Treglia, MS 857-364-2631 etreglia@bu.edu | |
| Principal Investigator: Margaret Naeser, PhD | |
| Principal Investigator: | Margaret Naeser, PhD | VA Medical Center, Jamaica Plain Campus |
More Information
No publications provided
| Responsible Party: | Department of Veterans Affairs |
| ClinicalTrials.gov Identifier: | NCT01782378 History of Changes |
| Other Study ID Numbers: | SPLD-014-12S, 1I01CX000524-01A1 |
| Study First Received: | January 30, 2013 |
| Last Updated: | March 12, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by Department of Veterans Affairs:
|
Persian Gulf Syndrome Veterans Health Executive Function Memory Attention |
Cognition Laser Therapy, Low-Level Phototherapy Light Therapy Depression |
Additional relevant MeSH terms:
|
Memory Disorders Persian Gulf Syndrome Neurobehavioral Manifestations Neurologic Manifestations |
Nervous System Diseases Signs and Symptoms Occupational Diseases |
ClinicalTrials.gov processed this record on May 16, 2013